Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription 26.08.2019 1 Am J Respir Crit Care Med 1 Ann Oncol 3 Ann Thorac Surg 3 BMC Cancer 1 Br J Cancer 2 Cancer Lett 2 Cancer Res 1 Cancer Sci 1 Carcinogenesis 2 Chest 3 Clin Cancer Res 1 Clin Exp Metastasis 1 Clin Lung Cancer 2 Clin Nucl Med 1 Eur J Cancer 1 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Surg Oncol 3 J Thorac Oncol 1 JAMA Oncol 2 Lancet Oncol 6 Lung Cancer 1 Mol Carcinog 2 Oncogene 1 Oncol Rep 1 Oncologist 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Respir Crit Care Med

1. BRIMS FJ, Kong K, Harris EJ, Sodhi-Berry N, et al
   Pleural Plaques and the Risk of Lung Cancer in Asbestos-exposed Subjects.
   Am J Respir Crit Care Med. 2019 Aug 21. doi: 10.1164/rccm.201901-0096.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
   Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
   Ann Oncol. 2019 Aug 21. pii: 5552557. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Thorac Surg

3. NAKAO K, Anraku M, Karasaki T, Kitano K, et al
   Impact of Previous Malignancy on Outcome in Surgically Resected Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2019 Aug 14. pii: S0003-4975(19)31174.
   PubMed     Text format     Abstract available
   
   
4. KANG CH
   The Anterolateral Approach in Robotic Lung Cancer Surgery.
   Ann Thorac Surg. 2019 Aug 14. pii: S0003-4975(19)31172.
   PubMed     Text format     Abstract available
   
   
5. SINGER ES, Merritt RE, D'Souza DM, Moffatt-Bruce SD, et al
   Patient Satisfaction after Lung Cancer Surgery: Do Clinical Outcomes affect HCAHPS Scores?
   Ann Thorac Surg. 2019 Aug 17. pii: S0003-4975(19)31190.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

6. CHOWDHURY P, Dey P, Ghosh S, Sarma A, et al
   Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
   BMC Cancer. 2019;19:829.
   PubMed     Text format     Abstract available
   
   
7. LUCCHETTA M, da Piedade I, Mounir M, Vabistsevits M, et al
   Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
   BMC Cancer. 2019;19:824.
   PubMed     Text format     Abstract available
   
   
8. DEL RE M, Rofi E, Cappelli C, Puppo G, et al
   The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.
   BMC Cancer. 2019;19:410.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

9. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
   Statins attenuate outgrowth of breast cancer metastases.
   Br J Cancer. 2018;119:1094-1105.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Lett

10. LEE YS, Jung YY, Park MH, Yeo IJ, et al
    Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
    Cancer Lett. 2018;433:156-164.
    PubMed     Text format     Abstract available
    
    
11. KUANG Y, Wang Q
    Iron and Lung Cancer.
    Cancer Lett. 2019 Aug 19. pii: S0304-3835(19)30438.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

12. VARTANIAN S, Lee J, Klijn C, Gnad F, et al
    ERBB3 and IGF1R signaling are required for Nrf2-dependent growth in KEAP1-mutant lung cancer.
    Cancer Res. 2019 Aug 15. pii: 0008-5472.CAN-18-2086.
    PubMed     Text format     Abstract available
    
    
13. CHUANG HC, Chang CC, Teng CF, Hsueh CH, et al
    MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-19-1402.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

14. KITA K, Fukuda K, Takahashi H, Tanimoto A, et al
    Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Cancer Sci. 2019 Aug 20. doi: 10.1111/cas.14171.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

15. WANG L, Shen S, Xiao H, Ding F, et al
    ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer via a STAT6-WWP2-P27 axis.
    Carcinogenesis. 2019 Aug 20. pii: 5552328. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Chest

16. COHEN SL, Wang JJ, Chan N, O'Connell W, et al
    Lung Cancer Screening CT: Gender-Specific Conversion Factors to Estimate Effective Radiation Dose from Dose Length Product.
    Chest. 2019 Aug 14. pii: S0012-3692(19)31454-0. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available
    
    
17. WANG N, Mengersen K, Tong S, Kimlin M, et al
    Lung cancer mortality in China: spatial and temporal trends among subpopulations.
    Chest. 2019 Aug 14. pii: S0012-3692(19)31452-7. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

18. LANDI L, Chiari R, Tiseo M, D'Inca F, et al
    Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.
    Clin Cancer Res. 2019 Aug 15. pii: 1078-0432.CCR-19-0994.
    PubMed     Text format     Abstract available
    
    
19. PAILLER E, Faugeroux V, Oulhen M, Mezquita L, et al
    Acquired Resistance Mutations to ALK-Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-1176.
    PubMed     Text format     Abstract available
    
    
20. CHEN K, Zhao H, Shi Y, Yang F, et al
    Perioperative dynamic changes in circulating tumor DNA in lung cancer patients (DYNAMIC).
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-1213.
    PubMed     Text format     Abstract available
    
    

    
    Clin Exp Metastasis

21. YANG J, Peng A, Wang B, Gusdon AM, et al
    The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis.
    Clin Exp Metastasis. 2019 Aug 16. pii: 10.1007/s10585-019-09985.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

22. CHENG H, Hosgood HD, Deng L, Ye K, et al
    Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2019 Jul 17. pii: S1525-7304(19)30207.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

23. IWANO S, Ito S, Kamiya S, Ito R, et al
    Utility of Metabolic Parameters on FDG PET/CT in the Classification of Early-Stage Lung Adenocarcinoma: Prediction of Pathological Invasive Size.
    Clin Nucl Med. 2019 Apr 19. doi: 10.1097/RLU.0000000000002591.
    PubMed     Text format     Abstract available
    
    
24. TRIPATHY S, Kumar R
    Role of Serial 68Ga DOTANOC PET-CT Scans in Follow-up of Metastatic Bronchial Carcinoid: 12 Year Follow-up From a Tertiary Care Institute.
    Clin Nucl Med. 2019 Apr 19. doi: 10.1097/RLU.0000000000002593.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

25. CHANG LC, Lim CK, Chang LY, Chen KY, et al
    Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Eur J Cancer. 2019;119:77-86.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

26. LI Z, Guo T, Fang L, Li N, et al
    MACC1 overexpression in carcinomaassociated fibroblasts induces the invasion of lung adenocarcinoma cells via paracrine signaling.
    Int J Oncol. 2019;54:1367-1375.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

27. DING X, Cheng J, Pang Q, Wei X, et al
    BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33642.
    PubMed     Text format     Abstract available
    
    
28. LIU C, Sun B, Hu X, Zhang Y, et al
    Stereotactic ablative radiotherapy for pulmonary recurrence-based oligometastatic non-small cell lung cancer: survival and prognostic value of regulatory T cells.
    Int J Radiat Oncol Biol Phys. 2019 Aug 19. pii: S0360-3016(19)33646.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

29. CHEN B, Xia W, Wang Z, Zhao H, et al
    Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.
    J Cancer Res Clin Oncol. 2019 Aug 19. pii: 10.1007/s00432-019-03006.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

30. STELZNER S, Radulova-Mauersberger O, Zschuppe E, Kittner T, et al
    Prognosis in patients with synchronous colorectal cancer metastases after complete resection of the primary tumor and the metastases.
    J Surg Oncol. 2019 Jun 5. doi: 10.1002/jso.25578.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

31. SPAGGIARI L, Sedda G, Maisonneuve P, Tessitore A, et al
    A brief report on survival after robotic lobectomy for early-stage lung cancer.
    J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30666.
    PubMed     Text format     Abstract available
    
    
32. FU F, Zhang Y, Wen Z, Zheng D, et al
    Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part solid or solid lesions.
    J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30664.
    PubMed     Text format     Abstract available
    
    
33. PARK BJ, Kim TH, Shin S, Kim HK, et al
    Recommended change in the N descriptor proposed by the International Association for the Study of Lung Cancer: a validation study.
    J Thorac Oncol. 2019 Aug 20. pii: S1556-0864(19)30670.
    PubMed     Text format     Abstract available
    
    

    
    JAMA Oncol

34. RENGAN R, Mick R, Pryma DA, Lin LL, et al
    Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
    JAMA Oncol. 2019 Aug 22. pii: 2748893. doi: 10.1001/jamaoncol.2019.2095.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

35. SOUQUET PJ, Couraud S
    Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30508.
    PubMed     Text format    
    
    
36. ANTONIA SJ, Borghaei H, Ramalingam SS, Horn L, et al
    Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30407.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer

37. SHOJI F, Takeoka H, Kozuma Y, Toyokawa G, et al
    Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2019;136:45-51.
    PubMed     Text format     Abstract available
    
    
38. GAUVAIN C, Vauleon E, Chouaid C, Le Rhun E, et al
    Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].
    Lung Cancer. 2019 Aug 14. pii: S0169-5002(18)30595.
    PubMed     Text format    
    
    
39. TANG W, Li X, Xie X, Sun X, et al
    EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2019;136:6-14.
    PubMed     Text format     Abstract available
    
    
40. CHOE EA, Cha YJ, Kim JH, Pyo KH, et al
    Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    Lung Cancer. 2019;136:30-36.
    PubMed     Text format     Abstract available
    
    
41. WANG G, Ionescu DN, Lee CH, Hiruki T, et al
    PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
    Lung Cancer. 2019;136:1-5.
    PubMed     Text format     Abstract available
    
    
42. LEE GJ, Lee H, Woo IS, Kim T, et al
    Erratum to "High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors" [Lung Cancer 132 (June) (2019) 9-16].
    Lung Cancer. 2019 Aug 13. pii: S0169-5002(19)30554.
    PubMed     Text format    
    
    

    
    Mol Carcinog

43. CUI J, Yin Z, Liu G, Chen X, et al
    Activating transcription factor 1 promoted migration and invasion in lung cancer cells through regulating EGFR and MMP-2.
    Mol Carcinog. 2019 Aug 16. doi: 10.1002/mc.23086.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

44. SALAMA MF, Liu M, Clarke CJ, Espaillat MP, et al
    PKCalpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.
    Oncogene. 2019 Aug 16. pii: 10.1038/s41388-019-0950.
    PubMed     Text format     Abstract available
    
    
45. YANG R, Liu N, Chen L, Jiang Y, et al
    GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH.
    Oncogene. 2019 Aug 15. pii: 10.1038/s41388-019-0909.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

46. SONG Z, Yin Y, Hao S, Wei J, et al
    JSK induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways.
    Oncol Rep. 2019;41:3475-3487.
    PubMed     Text format     Abstract available
    
    

    
    Oncologist

47. SPIGEL DR, Shipley DL, Waterhouse DM, Jones SF, et al
    A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
    Oncologist. 2019 Aug 16. pii: theoncologist.2018-0518.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

48. KOYAMA N, Iwai Y, Nagai Y, Aoshiba K, et al
    Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
    PLoS One. 2019;14:e0221718.
    PubMed     Text format     Abstract available
    
    
49. PUJOL JL, Coffy A, Camerini A, Kotsakis A, et al
    An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
    PLoS One. 2019;14:e0220988.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: